Hepatocellular carcinoma in tyrosinemia type 1 without clear increase of AFP.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 25667247.
- Also identified by DOI 10.1542/peds.2014-1913.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients with hereditary tyrosinemia type 1 have an elevated risk of developing hepatocellular carcinoma, especially if initiation of treatment with 2-(2-nitro-4-trifluoro-methylbenzoyl)-1,3-cyclohexanedione is delayed. Hepatocellular carcinoma can usually be suspected when there are increased α1-fetoprotein levels and characteristic imaging features. The present case shows that a lack of a clear increase in α1-fetoprotein should still lead to consideration of liver transplantation when imaging features change.
Medical subject headings
- Carcinoma, Hepatocellular
- Liver Neoplasms
- Tyrosinemias
- alpha-Fetoproteins